Found: 15
Select item for more details and to access through your institution.
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1633, doi. 10.1007/s10637-021-01149-8
- By:
- Publication type:
- Article
G‐CSF induces CD15<sup>+</sup> CD14<sup>+</sup> cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment.
- Published in:
- Clinical & Translational Immunology, 2022, v. 11, n. 5, p. 1, doi. 10.1002/cti2.1395
- By:
- Publication type:
- Article
Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.674720
- By:
- Publication type:
- Article
Immunotherapy of childhood Sarcomas.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00181
- By:
- Publication type:
- Article
Challenges of clinical trial design for targeted agents against pediatric leukemias.
- Published in:
- Frontiers in Oncology, 2015, v. 5, p. 1, doi. 10.3389/fonc.2014.00374
- By:
- Publication type:
- Article
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 3, p. 352, doi. 10.1111/j.1365-2141.2010.08251.x
- By:
- Publication type:
- Article
A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 573, doi. 10.1111/bjh.18560
- By:
- Publication type:
- Article
Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells.
- Published in:
- EMBO Reports, 2023, v. 24, n. 10, p. 1, doi. 10.15252/embr.202256279
- By:
- Publication type:
- Article
Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy.
- Published in:
- Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00553
- By:
- Publication type:
- Article
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1583, doi. 10.1007/s00262-021-03081-5
- By:
- Publication type:
- Article
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0612-6
- By:
- Publication type:
- Article
Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion.
- Published in:
- BioMed Research International, 2022, p. 1, doi. 10.1155/2022/9008685
- By:
- Publication type:
- Article
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 8, p. 2201, doi. 10.1002/ijc.32028
- By:
- Publication type:
- Article
The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100.
- Published in:
- International Journal of Cancer, 2018, v. 142, n. 7, p. 1490, doi. 10.1002/ijc.31170
- By:
- Publication type:
- Article
Molecular basis and current strategies of therapeutic arginine depletion for cancer.
- Published in:
- International Journal of Cancer, 2016, v. 139, n. 3, p. 501, doi. 10.1002/ijc.30051
- By:
- Publication type:
- Article